SEQSTER

SEQSTER is a healthcare technology company that has developed an operating system to aggregate disparate health data sources into a comprehensive, 360-degree view of a patient in real time. The company's platform enables the integration of electronic health records (EHRs), genomic data (DNA), wearable device data, and other healthcare information to create a longitudinal health record for each individual. SEQSTER's technology solves challenges related to data silos, patient engagement, and data interoperability across the healthcare continuum.

SEQSTER's operating system automates the collection of real-world data (RWD) and facilitates patient engagement through a digital front door. This approach leads to improved study participant retention and allows for the generation of real-world evidence (RWE) and long-term observational studies. The company's platform is compliant with HIPAA and FDA 21 CFR Part 11 regulations, ensuring data security and privacy.

Key customers and partnerships

SEQSTER partners with pharmaceutical companies, contract research organizations (CROs), and healthcare enterprises, providing them with accelerated access to de-identified, tokenized, real-time data. The company has nationwide coverage of EHRs from hospitals and medical groups, as well as access to genomic DNA, wearables, pharmacy, and social determinants of health data.

In October 2024, SESTER partnered with icometrix, an AI brain imaging solutions provider, to enhance neurological care and research. Through the partnership, the company's combined SEQSTER's 1-Click Records, which unifies patient health data from multiple sources, with icometrix's AI-powered brain imaging analysis tool, icobrain. The integration aimed to improve the detection, tracking, and management of neurological conditions such as Alzheimer's disease, multiple sclerosis, and traumatic brain injury.

In July 2024, SEQSTER partnered with Antidote Technologies, a digital patient engagement company, to improve clinical trial enrollment and timelines. Through the partnership, Antidote began leveraging SEQSTER's data platform to match patients to clinical trials based on their genomic data, lifestyle factors, and medical history. This partnership aimed to enhance Antidote's precision recruitment process, identify suitable participants more effectively, and reduce the time required to bring new treatments to market.

In December 2023, SEQSTER partnered with Atropos Health to establish turnkey patient registries for underrepresented populations, enabling rapid evidence generation for clinical development. The company also offers the Geneva OS and ChatRWD tools, which facilitate access to existing studies, active clinical trial designs, and the CRAFT Emulation Toolkit for improving trial recruitment and planning.